In some cases, a drug is better off in the hands of a smaller company that can devote more attention to its launch and commercialization; this may just be the case for chronic pain drug Nucynta, which is being acquired from drug giant Johnson & Johnson by Depomed Inc.
Depomed To Make Treasure Out of J&J Trash With Nucynta Buy
Depomed is leveraging all its value to bet on a drug that was virtually ignored by its big pharma owner with its billion-dollar buy of Janssen’s Nucynta.